Total results1,200
Search criteria
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.70High >= 0.60Medium >= 0.40Low >= 0.30| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| ITB6 | P18564 | Integrin beta-6 | Cancer-related genesDisease related genesHuman disease related genes | 1 | Amelogenesis imperfectaSolid tumour/cancer | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 3 | 0.53 | ||
| KCNV1 | Q6PIU1 | Potassium voltage-gated channel subfamily V member 1 (Neuronal potassium channel alpha subunit HNKA) (Voltage-gated potassium channel subunit Kv8.1) | 6 | Fusion and delivery mediation | 3 | 0.53 | ||||
| KI2L3 | P43628 | Killer cell immunoglobulin-like receptor 2DL3 (CD158 antigen-like family member B2) (KIR-023GB) (Killer inhibitory receptor cl 2-3) (NKAT2a) (NKAT2b) (Natural killer-associated transcript 2) (NKAT-2) (p58 natural killer cell receptor clone CL-6) (p58 NK receptor CL-6) (p58.2 MHC class-I-specific NK receptor) (CD antigen CD158b2) | 1 | Immune mediation | 3 | 0.53 | ||||
| LDLR | P01130 | Low-density lipoprotein receptor (LDL receptor) | Disease related genesHuman disease related genesMetabolic proteins | 1 | Adhesion and uptake mediationFusion and delivery mediationImmune mediation | 3 | 0.53 | |||
| MRP5 | O15440 | ATP-binding cassette sub-family C member 5 (EC 7.6.2.-) (EC 7.6.2.2) (Multi-specific organic anion transporter C) (MOAT-C) (Multidrug resistance-associated protein 5) (SMRP) (pABC11) | Cancer-related genesEnzymesMetabolic proteins | 13 | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 3 | 0.53 | |||
| MTR1L | Q13585 | Melatonin-related receptor (G protein-coupled receptor 50) (H9) [Cleaved into: C-terminal domain] | G-protein coupled receptorsPlasma proteinsPredicted membrane proteins | 7 | Other mediation | 3 | 0.53 | |||
| NMDE2 | Q13224 | Glutamate receptor ionotropic, NMDA 2B (GluN2B) (Glutamate [NMDA] receptor subunit epsilon-2) (N-methyl D-aspartate receptor subtype 2B) (NMDAR2B) (NR2B) (N-methyl-D-aspartate receptor subunit 3) (NR3) (hNR3) | Disease related genesFDA approved drug targetsHuman disease related genes | 3 | EpilepsyIntellectual disability | Clinical-translation mediationFusion and delivery mediationReceptor-signaling mediation | 3 | 0.53 | ||
| OX2G | P41217 | OX-2 membrane glycoprotein (CD antigen CD200) | CD markersPredicted intracellular proteinsPredicted membrane proteins | 1 | Acute myeloid leukaemiaMature B-cell leukaemiaSolid tumour/cancer | Clinical-translation mediationFusion and delivery mediationImmune mediation | 3 | 0.53 | ||
| 5HT1B | P28222 | 5-hydroxytryptamine receptor 1B (5-HT-1B) (5-HT1B) (S12) (Serotonin 1D beta receptor) (5-HT-1D-beta) (Serotonin receptor 1B) | FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins | 7 | Alzheimer diseaseAnxiety disorderAttention deficit hyperactivity disorder | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 2 | 0.53 | ||
| 5HT2B | P41595 | 5-hydroxytryptamine receptor 2B (5-HT-2B) (5-HT2B) (Serotonin receptor 2B) | FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins | 7 | Anxiety disorderAttention deficit hyperactivity disorderCoronary atherosclerosis | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.53 |